Hemostatic compositions

a composition and composition technology, applied in the field of hemostatic compositions, can solve the problems that the hemostatic compositions used in wound healing failed to induce hemostasis, and achieve the effects of improving hemostasis, improving tissue adhesion, and improving hemostatic properties

Inactive Publication Date: 2013-04-18
BAXTER INT INC +1
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a composition that improves hemostasis (the process of stopping bleeding) and adheres to tissue well when applied to a wound. The composition can be made by mixing a biocompatible polymer and a hydrophilic polymer in a certain ratio. The composition can be reconstituted to a flowable form and is suitable for treating injuries such as wounds, bleeding tissue, and bone defects. The method for preparing the composition is simple and efficient, making it ready for use in emergency situations.

Problems solved by technology

On the other hand, it has been found that previous hemostatic compositions for wound healing failed to induce hemostasis at conditions with impaired hemostasis (e.g. after heparinization).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemostatic compositions
  • Hemostatic compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Mixture Neutral

[0083]A mixture was prepared by mixing a specific amount of crosslinked gelatin particles with 20 wt % of NHS-PEG. Typically, 6g of gelatin particles in a 50 ml test tube were mixed with 1.2 g of NHS-PEG using end-over-end-mixer for at least 30 minutes in order to obtain a homogenous mixture of both components. From the mixture obtained, 0.96 g were weighted in a 5 ml syringe. As a diluent 3.5 ml of saline solution in a 5 ml syringe with female luer connector were used to hydrate the powder component before application to a bleeding site.

[0084]Hydration of the particulate component with the diluent was achieved by connection of both syringes and transforming the diluent to the syringe filled with the gelatin. In order to obtain a homogenous product, the content of the syringes was pushed back and forth at least 21 times. After hydration, a product obtained was allowed to hydrate for 2 minutes. A product obtained was applied to a bleeding wound using appropriate applic...

example 2

Mixture Basic

[0085]In order to obtain a faster reactive flowable hemostat the mixture as described in Example 1 was hydrated by using 3.5 ml of a basic buffer having pH of 9.5 as a diluent.

[0086]A product obtained was allowed to hydrate for 2 minutes and was applied to a blending wound.

example 3

Mixture Acidic

[0087]In order to obtain a reactive flowable hemostat with prolonged stability the mixture as described in Example 1 was hydrated with 3.5 ml of saline solution having pH adjusted to 1.5 with 1 M of HCl as a diluent.

[0088]A product obtained was allowed to hydrate for 2 minutes and was applied to a bleeding wound.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Hydrophilicityaaaaaaaaaa
Biocompatibilityaaaaaaaaaa
Electrophilicaaaaaaaaaa
Login to view more

Abstract

The invention discloses a hemostatic composition comprising:a) a biocompatible polymer in particulate form suitable for use in hemostasis, andb) one hydrophilic polymeric component comprising reactive groups.

Description

[0001]This application claims the benefit of U.S. Ser. No. 61 / 545,909 filed Oct. 11, 2011, which is incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to hemostatic compositions and processes for making such compositions.BACKGROUND OF THE INVENTION[0003]Hemostatic compositions in dry storage-stable form that comprise biocompatible, biodegradable, dry stable granular material are known e.g. from WO98 / 008550A or WO 2003 / 007845A. These products have been successfully applied on the art for hemostasis. Floseal® is an example for a powerful and versatile hemostatic agent consisting of a granular gelatin matrix swollen in a thrombin-containing solution to form a flowable paste.[0004]Since such products have to be applied to humans, it is necessary to provide highest safety standards for quality, storage-stability and sterility of the final products and the components thereof. On the other hand, manufacturing and handling should be made as convenient...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61K31/765
CPCA61K31/765A61K38/42A61L24/043A61L26/0052A61L2400/04A61K38/17A61K38/38A61L26/008A61L24/0031C08L71/02C08L89/00A61P17/02
Inventor HEDRICH, HANS CHRISTIANHOEFINGHOFF, JORISGORNA, KATARZYNA
Owner BAXTER INT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap